Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04181723 · ClinicalTrials.gov registry record · Phase 3
Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)
A Phase 3 study, sponsored by ACADIA Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 187
- Enrollment target
NCT04181723 is a Phase 3 study that has completed, run by ACADIA Pharmaceuticals. The registered enrollment target is 187 participants.
The verdict
NCT04181723, a Phase 3 study, has completed, sponsored by ACADIA Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 187 participants
- Enrollment target
Study Summary
To investigate the efficacy of treatment with oral trofinetide versus placebo in females with Rett syndrome
Interventions
- OTHER Placebo
- DRUG Trofinetide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 187 participants |
| Start Date | 2019-11-06 |
| Est. Completion | 2021-10-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04181723
The ClinicalTrials.gov registry entry for NCT04181723 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 187 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ACADIA Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04181723 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04181723 about?
NCT04181723 is a clinical study titled "Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)". To investigate the efficacy of treatment with oral trofinetide versus placebo in females with Rett syndrome
What is the current status of trial NCT04181723?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 187 participants. The study started on 2019-11-06. Estimated completion is 2021-10-28.
What interventions are being tested in trial NCT04181723?
The interventions under investigation include: Placebo (OTHER), Trofinetide (DRUG).
Who is sponsoring clinical trial NCT04181723?
This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.